Skip to main content
. 2017 Jun 7;34(9):1784–1795. doi: 10.1007/s11095-017-2183-6

Fig. 4.

Fig. 4

Relationship between erenumab concentrations and dermal blood flow (DBF) inhibition. The symbols represent individual observations. IV, intravenous; Q4W, every 4 weeks; SC subcutaneous.